Cervical cancer is one of the common malignant tumors in women. Early detection and timely treatment can achieve very good results, with a cure rate of about 90%. Therefore, it is very important for women who have already had sex and are over 25 years old to be screened for cervical cancer early. It has been confirmed that persistent infection with high-risk human papilloma (HPV) virus is closely associated with cervical cancer, and HPV virus is a mucosal and cutaneous epithelium-loving virus with more than 200 types identified, among which about 16 types are highly associated with cervical cancer. Therefore, special testing for HPV viruses, especially high-risk HPV viruses, has become an important tool for cervical cancer screening and is increasingly used in clinical practice, and its test results are an important basis for cervical cancer pre-screening. In 2011, the International Agency for Research on Cancer (IARC) newly confirmed that among 16 high-risk HPV viruses, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 were confirmed to be adequately associated with cervical cancer. While type 68 is a rare high-risk HPV virus model, it has a strong association with cervical cancer, so it is also treated as a high-risk type. There are a variety of HPV-specific testing methods, including PCR hybridization capture, in situ hybridization, hybridization by microarray technology, real-time fluorescent PCR and speckle blotting, each with different sensitivities and specificities. The two most commonly used methods for detection of high-risk HPV viruses are fluorescent quantitative PCR and HC2-HPV-DNA. Among them, HC2-HPV-DNA is the only test that has been certified by the FDA, CE, and the Chinese FDA, which has higher reliability and biosafety and is currently the gold standard for detection of high-risk HPV viruses. In 2013, the American Society for Colposcopy and Cervical Pathology, in its new guidelines on cervical cancer screening, recommended that the best screening protocol for cervical cancer in women over 30 years of age is a combination of HC-2 testing and cytology (TCT), which is the screening method with the lowest missed diagnosis rate. HC-2 is a molecular biology technique that uses the principle of hybridization capture signal amplification to directly detect HPV-DNA, which can cause cervical cancer, and this test can detect the 13 high-risk HPV types mentioned above at one time. It is more reliable than the method of detecting one or several HPVs alone. And there are several advantages of HC2-HPV-DNA test as follows: 1. few interfering factors during the experiment, no cross-reactivity, avoiding false-positive results; 2. high sensitivity, no enzyme inhibition reaction, avoiding false-negative results, stable and reliable test results; 3. no virus replication during the experiment, good biosafety; 4. simple method, easy to operate. Regarding the determination of the test result of HC-2, it is positive when HPV-DNA ≧ 1.0pg/ml. Some studies have indicated that the occurrence of cervical cancer is closely related to the duration of high-risk HPV infection and viral load, and when the viral load is higher and lasts longer, the risk of cervical cancer is relatively greater. However, in my years of actual clinical summary, my understanding of the high or low value of HPV in HC-2 test is that the high or low value can have the following effects: First, because cervical high-risk HPV infection can cause simultaneous infection at multiple points on the cervical canal and cervical surface, and the depth of latency of the virus infection is not consistent, and we are checking from the surface of the cervical canal when we do the examination, if the virus is located in the shallow part or surface at this time, and the virus has not formed yet. If the virus is located in the superficial part or surface, and the virus has not yet formed focal changes, the value will be relatively high. Secondly, when the virus has started to replicate, change and become diseased, forming a localized state change, or is no longer located on the surface, the value may not be high. In the matter of seeing a doctor, prevention is much more important than treatment. Make HC-2 screening a routine part of your own gynecological examination and give early and aggressive treatment to clear the virus once a high-risk HPV infection is detected and if the virus is still persistent during regular observation at a later stage. It is far more meaningful to nip the worse outcome in the cradle before it happens than to mend the fold after cervical cancer has occurred.